William R. Grove

1000 total citations
30 papers, 779 citations indexed

About

William R. Grove is a scholar working on Oncology, Molecular Biology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, William R. Grove has authored 30 papers receiving a total of 779 indexed citations (citations by other indexed papers that have themselves been cited), including 11 papers in Oncology, 9 papers in Molecular Biology and 6 papers in Pulmonary and Respiratory Medicine. Recurrent topics in William R. Grove's work include Cancer Treatment and Pharmacology (5 papers), Chronic Lymphocytic Leukemia Research (3 papers) and Cancer therapeutics and mechanisms (3 papers). William R. Grove is often cited by papers focused on Cancer Treatment and Pharmacology (5 papers), Chronic Lymphocytic Leukemia Research (3 papers) and Cancer therapeutics and mechanisms (3 papers). William R. Grove collaborates with scholars based in United States, New Zealand and Belgium. William R. Grove's co-authors include Gulshan Bhatia, Andrea Polesky, Clarence L. Fortner, William P. Reed, Mark M. Applefeld, David S. Roffman, Kathryn A. Newman, Casey Cunningham, John Nemunaitis and A. S. Williams and has published in prestigious journals such as The American Journal of Cardiology, Annals of Oncology and American Heart Journal.

In The Last Decade

William R. Grove

29 papers receiving 717 citations

Peers

Countries citing papers authored by William R. Grove

Since Specialization

Citations

This map shows the geographic impact of William R. Grove's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by William R. Grove with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites William R. Grove more than expected).

Fields of papers citing papers by William R. Grove

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by William R. Grove. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by William R. Grove. The network helps show where William R. Grove may publish in the future.

Co-authorship network of co-authors of William R. Grove

This figure shows the co-authorship network connecting the top 25 collaborators of William R. Grove. A scholar is included among the top collaborators of William R. Grove based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with William R. Grove. William R. Grove is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Gemcitabine plus CI-994 offers no advantage over gemcitabine alone in the treatment of patients with advanced pancreatic cancer: results of a phase II randomized, double-blind, placebo-controlled, multicenter study 2006 ·Annals of Oncology ·David Richards, Kristi A. Boehm, David Waterhouse, D. J. Th. Wagener, Smitha Krishnamurthi, Alexander S. Rosemurgy, William R. Grove, Karen MacDonald, (unknown), (unknown), (unknown)	88
2	Peripheral Tuberculous Lymphadenitis 2005 ·Medicine ·Andrea Polesky, William R. Grove, Gulshan Bhatia	118
3	Phase I Study of Oral CI-994 in Combination with Carboplatin and Paclitaxel in the Treatment of Patients with Advanced Solid Tumors 2004 ·Cancer Investigation ·L. Pauer, (unknown), Casey Cunningham, A. S. Williams, William R. Grove, Alan J. Kraker, Stephen C. Olson, John Nemunaitis	94
4	Phase I Study of Oral CI-994 in Combination with Gemcitabine in Treatment of Patients with Advanced Cancer 2003 ·The Cancer Journal ·John Nemunaitis, Douglas Orr, (unknown), Casey Cunningham, A. S. Williams, Robert Mennel, William R. Grove, Stephen C. Olson	49
5	A phase II trial of CI-958 in patients with hormone-refractory prostate cancer 1999 ·Cancer Chemotherapy and Pharmacology ·Paul V. Woolley, Fuad S. Freiha, David C. Smith, (unknown), (unknown), (unknown), William R. Grove, Donald L. Trump	6
6	Phase II study of i.v. CI-980 in patients with advanced platinum refractory epithelial ovarian carcinoma 1998 ·Anti-Cancer Drugs ·Andrzej P. Kudelka, Annette Hasenburg, Claire F. Verschraegen, Creighton L. Edwards, Christina A. Meyers, (unknown), Ralph S. Freedman, Arthur Forman, Charles A. Conrad, William R. Grove, Axel Grothey, John J. Kavanagh	10
7	Phase II Trial of Intravenous CI-980 (NSC 370147) in Patients with Metastatic Colorectal Carcinoma 1997 ·American Journal of Clinical Oncology ·Richard Pazdur, Christina Meyers, (unknown), James L. Abbruzzese, Yehuda Z. Patt, William R. Grove, Jaffer A. Ajani	10
8	A phase II trial of CI-921 in advanced malignancies 1992 ·Investigational New Drugs ·Nancy T. Sklarin, (unknown), William R. Grove, (unknown), Abraham Mittelman, Jean A. Maroun, James A. Stewart, Francisco Robert, James H. Doroshow, Peter J. Rosen, Jacques Jolivet, John C. Ruckdeschel, Nicholas J. Robert, E Vélez-García, Daniel E. Bergsagel, Lawrence Panasci, (unknown), J Longueville, (unknown), C D Kowal	19
9	Phase II study of the amsacrine analogue CI-921 (NSC 343499) in non-small cell lung cancer 1991 ·European Journal of Cancer and Clinical Oncology ·Vernon Harvey, Janet Hardy, (unknown), William R. Grove, Bruce C. Baguley	17
10	3-Deazaguanine: Report of a phase I trial and drug-related cardiac toxicity 1990 ·Investigational New Drugs ·Kim Margolin, J. H. Doroshow, Lucille Leong, Steven A. Akman, Brian I. Carr, (unknown), (unknown), William R. Grove, (unknown), David M. Goldberg	2
11	Treatment of metastatic malignant melanoma with trimetrexate: A phase II study 1990 ·Medical and Pediatric Oncology ·(unknown), David A. Goldberg, James H. Doroshow, Lucille Leong, Kim Margolin, William R. Grove, Brian I. Carr, Steven A. Akman	6
12	Phase I clinical and pharmacokinetic study of trimetrexate using a daily x5 schedule. 1988 ·PubMed ·James A. Stewart, John J. McCormack, W P Tong, (unknown), John D. Roberts, (unknown), Lloyd R. Whitfield, Larry D. Haugh, William R. Grove, Anthony Lopez	26
13	Trimetrexate and cyclophosphamide for metastatic inoperable nonsmall cell lung cancer. 1988 ·PubMed ·K. Mattson, Paula Maasilta, L. Tammilehto, Lars R. Holsti, William R. Grove	10
14	An Overview of Cancer Chemotherapy 1985 ·Journal of Pharmacy Technology ·Rebecca S. Finley, William R. Grove, Clarence L. Fortner	2
15	Combination Antiemetic Therapy in the Control of Chemotherapy-Induced Emesis 1985 ·Drug Intelligence & Clinical Pharmacy ·Clarence L. Fortner, Rebecca S. Finley, William R. Grove	10
16	Intermittent dobutamine hydrochloride infusions in outpatients with chronic congestive heart failure. 1985 ·PubMed ·David S. Roffman, Mark M. Applefeld, William R. Grove, (unknown), (unknown), Kathryn A. Newman, William P. Reed	28
17	Evaluation of Measures of the Quality of Life in Patients with Advanced Cancer 1983 ·Queensland's institutional digital repository (The University of Queensland) ·(unknown), (unknown), (unknown), William R. Grove	3
18	Intermittent, continuous outpatient dobutamine infusion in the management of congestive heart failure 1983 ·The American Journal of Cardiology ·Mark M. Applefeld, Kathryn A. Newman, William R. Grove, (unknown), David S. Roffman, William P. Reed, Steven E. Linberg	59
19	Fat emulsion vehicle for intravenous administration of an aqueous insoluble drug 1975 ·American Journal of Health-System Pharmacy ·Clarence L. Fortner, William R. Grove, (unknown), Michael Walker	22
20	Subcellular distribution of 125I-labeled bovine growth hormone in rat liver and kidney 1972 ·Biochimica et Biophysica Acta (BBA) - General Subjects ·William R. Grove, (unknown), Gladys Sisco Bayse	17

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact